Abstract
The microtubule-targeting taxanes are important in
breast cancer therapy, but no predictive biomarkers have yet
been identified with sufficient scientific evidence to allow
clinical routine use. The purposes of the present study were
to develop a cell-culture-based discovery platform for docetaxel
resistance and thereby identify key molecular mechanisms
and predictive molecular characteristics to docetaxel
resistance. Two docetaxel-resistant cell lines, MCF7RES and
MDARES, were generated from their respective parental cell
lines MCF-7 and MDA-MB-231 by stepwise selection in docetaxel
dose increments over 15 months. The cell lines were
characterized regarding sensitivity to docetaxel and other chemotherapeutics
and subjected to transcriptome-wide mRNA
microarray profiling. MCF7RES and MDARES exhibited a biphasic
growth inhibition pattern at increasing docetaxel
concentrations. Gene expression analysis singled out
ABCB1, which encodes permeability glycoprotein (Pgp), as
the top upregulated gene in both MCF7RES and MDARES.
Functional validation revealed Pgp as a key resistance mediator
at low docetaxel concentrations (first-phase response),
whereas additional resistance mechanisms appeared to be
prominent at higher docetaxel concentrations (second-phase
response). Additional resistance mechanisms were indicated
by gene expression profiling, including genes in the
interferon-inducible protein family in MCF7RES and cancer
testis antigen family in MDARES. Also, upregulated expression
of various ABC transporters, ECM-associated proteins,
and lysosomal proteins was identified in both resistant cell
lines. Finally, MCF7RES and MDARES presented with crossresistance
to epirubicin, but only MDARES showed cross-
resistance to oxaliplatin. In conclusion, Pgp was identified as a
key mediator of resistance to low docetaxel concentrations
with other resistance mechanisms prominent at higher docetaxel
concentrations. Supporting Pgp upregulation as one major
mechanism of taxane resistance and cell-line-specific alterations
as another, bothMCF7RES andMDARES were crossresistant
to epirubicin (Pgp substrate), but only MDARES was
cross-resistant to oxaliplatin (non-Pgp substrate).
Original language | English |
---|---|
Journal | Tumor Biology |
Volume | 36 |
Issue number | 6 |
Pages (from-to) | 4327-4338 |
Number of pages | 14 |
ISSN | 1010-4283 |
DOIs | |
Publication status | Published - 2015 |
Keywords
- Breast cancer
- Docetaxel
- Resistance
- Microarray analysis
- Gene set enrichment analysis
- Pgp